The abstract is read at the publisher; the summary is JClub's.
Targetable alterations in glioblastoma are mapped across major drug target classes, but intratumoural heterogeneity and limited CNS delivery constrain targeted therapy benefits.
- Why it matters: Targeted therapies have shown only limited benefit in glioblastoma despite deep molecular characterization, leaving a gap in how to match drugs to functional tumour states.
- What they did: This Review synthesizes therapeutic landscapes and strategies, including improved tumour profiling via multiregional sampling, blood-brain penetration approaches, and emerging modalities like antibody-drug conjugates and theranostics.
- The result: It highlights tumor heterogeneity, extrachromosomal DNA dynamics, and novel trial and liquid biopsy monitoring strategies as key to overcoming resistance and better aligning therapies with tumour biology.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.